From MS to NMOSD to early Alzheimer's disease, neurologic mAbs are delivering proven clinical benefit. But as efficacy becomes less of a differentiator, what determines whether these therapies reach patients? In this art...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
From confidence to capital: Positioning biotech for the next growth cycle
How can biotechs position themselves for the next growth cycle? Deepali Suri shares insights on investor readiness, AI, global development strategies and emerging opportunities across biotech.
-
Why Europe, not America, may be Chinese sponsors’ smartest move
As Chinese sponsors expand globally, Europe offers a stable, science-driven regulatory environment and broad market access across the region. Planning for EMA requirements from the outset helps accelerate approvals, minimise costly study adaptations and support long-term commercial success.
-
Chinese drugmakers with big ambitions struggle to recruit staff for global expansion
China's rapid rise as a hub for testing experimental, next-generation medicines is outpacing the industry's ability to build the workforce needed to take those products global.
-
It’s complicated! When APAC global ambition meets regulatory reality
While not all sponsors plan to market treatments beyond the country of origin, many do. Those sponsors with global ambitions must decide which regulatory route offers the most strategic advantages and which market, particularly between the EU and US.
-
Banyan BioInnovations debuts with $100M+ and ICON
A new biotech investment firm launches with more than $100 million in initial commitments from life science investors. ICON is both a strategic collaborator and an equity investor.
-
Banyan BioInnovations launces with ICON support
$100M Biotech investment fund announces collaboration with ICON designed to improve trial execution and design, as well as commercialisation strategy.
-
When ambition meets ambiguity: The trends and sentiments shaping biotech in 2026
Deepali Suri, President ICON Biotech, provides insights into what biotech leaders anticipate in the coming two years, the therapies and modalities they’re focused on now and what macro and micro factors are impacting their operations.
-
China biotech continues its growth trajectory
Yao Zhong, vice president general manager for ICON China Mainland and Hong Kong, discusses latest survey results on the Chinese biotech market.
-
2025 in Review: Global biotech and funding trends
In this interview, Deepali Suri, President of ICON Biotech, breaks down the key trends shaping today’s biotech industry and their global impact. Using insights from ICON’s global and China biotech surveys, capturing input from more than 260 biotech leaders worldwide, Suri highlights emerging therapeutic innovations, the growing influence of AI in R&D, and how geopolitical tensions are redefining international drug development strategies.
-
The formula for biotech success in 2026: Confidence, resilience and funding
For biotech companies the past two years have been challenging. In 2025 ICON Biotech conducted a follow-up survey of biotech leaders, previously carried out in 2023. The new results show changing trends in the risks, challenges and opportunities in the biotech sector.
